Navigation Links
Medisafe 1 Technologies Announces 1-5 Stock Dividend

Medisafe 1 Technologies Announces 1-5 Stock Dividend -- JERUSALEM, September 1, 2010 /PRNewswire-FirstCall/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Dividends Click to view news release full screen  

Medisafe 1 Technologies Announces 1-5 Stock Dividend


JERUSALEM, September 1, 2010 /PRNewswire-FirstCall/ -- Medisafe 1 Technologies Corp. (OTC: MFTH), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company will be issuing and completing a stock dividend on its common shares of 1-5.

The Company anticipates the stock dividend will be payable on or about September 20 2010 to the shareholders of record on September 17 2010 and is subject to FINRA approval. When the stock dividend becomes effective, shareholders of each one restricted stock will receive an additional 4 shares of restricted stock and each shareholder of one unrestricted stock will receive an additional 4 shares of unrestricted stock. Medisafe 1 Technologies currently has 10,000,000 shares outstanding. The issuance of the dividend will increase the total shares outstanding to 50,000,000. Medisafe 1 expects the Boards decision will improve liquidity and trading volume in the Company's stock.

About Medisafe 1 Technologies

Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle. Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.

Forward-Looking Statements

This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. Medisafe 1 Technologies Corp. public filings may be viewed at

Contact: Jacob Elhadad CEO +972-524440000

SOURCE Medisafe 1 Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies
2. TriLink BioTechnologies to Sponsor Take Me Out to the Ballgame, a SAY San Diego Event Benefiting San Diego Families in Need
3. Life Technologies and SG Biofuels Complete Sequence of Jatropha Genome
4. Novel Stem Cell Therapy From Cellonis Biotechnologies Can Help Children With Diabetes Get Back Their Normal Lives
5. Looking to leap forward on laser and photodetector technologies
6. MultiCell Technologies Applies for Qualifying Therapeutic Discovery Project Grants
7. Reportlinker Adds Bioinformatics Market - Advanced Technologies, Global Forecast and Winning Imperatives (2009 - 2014)
8. Webcast Alert: Senesco Technologies (SNT) Announces the LHA Life Sciences & Med Tech Day 2010 Presentation
9. OvaGene Oncology Licenses Gene-Based Technologies to Develop Novel Endometrial and Cervical Cancer Assays
10. SeqWright Expands Genomics Services Offering Through New Partnership With RainDance Technologies
11. Palatin Technologies, Inc. to Raise $2.0 Million Dollars in Registered Direct Offering
Post Your Comments:
(Date:11/25/2015)... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) ... chat discussion at the Piper Jaffray 27th Annual Healthcare ... discussion is scheduled for Wednesday, December 2, at 8:00 ... replay will be available for 14 days after the ... NormartVP, Corporate Communications and Business Development , BrewLife(858) 875-8629 ...
(Date:11/24/2015)... 24, 2015 Cepheid (NASDAQ: CPHD ) ... the following conference, and invited investors to participate via ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern ... New York, NY      Tuesday, December 1, ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... behalf of the Toronto Stock Exchange, confirms that as ... no corporate developments that would cause the recent movements ... --> About Aeterna Zentaris Inc. ... --> Aeterna Zentaris is a specialty biopharmaceutical company ...
(Date:11/24/2015)... , November 24, 2015 SHPG ) announced ... in the Piper Jaffray 27 th Annual Healthcare Conference in ... 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). --> ... Financial Officer, will participate in the Piper Jaffray 27 th ... NY on Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 ...
Breaking Biology Technology:
(Date:11/16/2015)... Nov 16, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced expansion of its TDDI product ... touch controller and display driver integration (TDDI) solutions ... These new TDDI products add to the previously-announced ... TD4302 (WQHD resolution), and TD4322 (FHD resolution) solutions. ...
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
Breaking Biology News(10 mins):